The Effect of Mill Type on Two Dry-Granulated Placebo Formulations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Effect of Mill Type on Two Dry-Granulated Placebo Formulations
The authors evaluate the effect of various mill types on particle-size distribution, flowability, tabletability, and compactibility.


Pharmaceutical Technology
Volume 32, Issue 11, pp. 72-86


Table I: Microcrystalline cellulose–dibasic calcium phosphate (2:1) placebo formulation.
Gran-U-Lizer. The Gran-U-Lizer is a nonattrition size-reduction mill. It uses roller-mill technology that contols particle-size reduction through roll-surface texture (i.e., roll type), roll speed, and roll gap. According to MPE, the Gran-U-Lizer operates through the use of shear, in contrast to impact used by conventional size-reduction equipment. The Gran-U-Lizer achieves a narrower particle-size distribution with fewer fines by eliminating the attrition inherent in other milling designs. The laboratory model Gran-U-Lizer requires several passes through the rolls using various roll types, roll speeds, and roll gaps to achieve the desired particle-size distribution. All milling trials using the Gran-U-Lizer roller mill were conducted at MPE's Chicago site.

Formulation


Table II: Microcrystalline cellulose–lactose (2:1) placebo formulation.
Two IR, dry-granulation placebo formulations (see Tables I and II) were selected to evaluate mill performance. Roller-compaction conditions were established using the Gerteis Mini-Pactor roller compactor to produce ribbon at a target solid fraction of 0.7 at an approximate thickness of 2.5 mm. Ribbon was manufactured from both formulations and characterized for solid fraction, tensile strength, and thickness. Roller-compaction bypass was measured to establish the fines level within the compacted ribbon before milling.

Ribbon characterization


Figure 1: Measurements of ribbon dimensions. (AUTHORS)
Solid fraction. Ribbon samples were prepared by cutting the compacted ribbon into rectangular shapes of approximately 10 x 22 mm using a jeweler's table saw. Figure 1 demonstrates how the ribbon sample was prepared. The cut ribbon sample was measured using calipers to determine the envelope density.

The solid fraction of each ribbon sample was determined according to a relationship that can be expressed by the following equation:




in which w is the ribbon width, l is the ribbon length, t is the ribbon thickness, m is the ribbon mass, V s is the volume of the roller serrations, and ρ t is the true density of the material.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
67%
Facility/environment problems
0%
Process development problems
0%
Production equipment downtime
0%
Raw material supply problems
33%
Regulatory restrictions
0%
Business decisions to limit production
0%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: Pharmaceutical Technology,
Click here